Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2012 Jun 5;106(12):2016-24. doi: 10.1038/bjc.2012.160. Epub 2012 May 15.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.

Jakubowska A1, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN, Thomassen M, Paligo M, Aretini P; SWE-BRCA, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M; HEBON, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P; EMBRACE, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B; GEMO Study Collaborators, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X; KConFab, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J; CIMBA, the Consortium of Investigators of Modifiers of BRCA1/2-Related Cancer.

Collaborators (235)

Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Miedzybrodzka Z, Gregory H, Morrison P, Jeffers L, Cole T, Ong KR, Hoffman J, Donaldson A, James M, Paterson J, Downing S, Taylor A, Murray A, Rogers MT, McCann E, Kennedy MJ, Barton D, Porteous M, Drummond S, Brewer C, Kivuva E, Searle A, Goodman S, Hill K, Davidson R, Murday V, Bradshaw N, Snadden L, Longmuir M, Watt C, Gibson S, Haque E, Tobias E, Duncan A, Izatt L, Jacobs C, Langman C, Whaite A, Dorkins H, Barwell J, Adlard J, Chu C, Miller J, Ellis I, Houghton C, Evans DG, Lalloo F, Taylor J, Side L, Male A, Berlin C, Eason J, Collier R, Douglas F, Claber O, Jobson I, Walker L, McLeod D, Halliday D, Durell S, Stayner B, Eeles R, Shanley S, Rahman N, Houlston R, Bancroft E, D'Mello L, Page E, Ardern-Jones A, Kohut K, Wiggins J, Castro E, Mitra A, Robertson L, Cook J, Quarrell O, Bardsley C, Hodgson S, Goff S, Brice G, Winchester L, Eddy C, Tripathi V, Attard V, Eccles D, Lucassen A, Crawford G, McBride D, Smalley S, Sinilnikova O, Mazoyer S, Barjhoux L, Verny-Pierre C, Giraud S, Léone M, Stoppa-Lyonnet D, Gauthier-Villars M, Buecher B, Houdayer C, Moncoutier V, Belotti M, Tirapo C, de Pauw A, Bressac-de-Paillerets B, Byrde V, Caron O, Lenoir G, Bignon YJ, Uhrhammer N, Lasset C, Bonadona V, Hardouin A, Berthet P, Sobol H, Bourdon V, Noguchi T, Remenieras A, Eisinger F, Coulet F, Colas C, Soubrier F, Coupier I, Pujol P, Peyrat JP, Fournier J, Révillion F, Vennin P, Adenis C, Rouleau E, Lidereau R, Demange L, Nogues C, Muller D, Fricker JP, Barouk-Simonet E, Bonnet F, Bubien V, Sevenet N, Longy M, Toulas C, Guimbaud R, Gladieff L, Feillel V, Leroux D, Dreyfus H, Rebischung C, Peysselon M, Coron F, Faivre L, Prieur F, Lebrun M, Kientz C, Ferrer SF, Frénay M, Vénat-Bouvet L, Delnatte C, Mortemousque I, Lynch HT, Snyder CL, Hogervorst FB, Verhoef S, Verheus M, van't Veer LJ, van Leeuwen FE, Rookus MA, Collée M, van den Ouweland AM, Jager A, Hooning MJ, Tilanus-Linthorst MM, Seynaeve C, van Asperen CJ, Wijnen JT, Vreeswijk MP, Tollenaar RA, Devilee P, Ligtenberg MJ, Hoogerbrugge N, Ausems MG, van der Luijt RB, Aalfs CM, van Os TA, Gille JJ, Waisfisz Q, Meijers-Heijboer HE, Gomez-Garcia EB, van Roozendaal CE, Blok MJ, Caanen B, Oosterwijk JC, van der Hout AH, Mourits MJ, Vasen HF, Szabo CI, Zikan M, Pohlreich P, Kleibl Z, Foretova L, Eva M, Miroslava L, Claes K, De Leeneer K, Poppe B, De Paepe A, Karlsson P, Nordling M, Bergman A, Einbeigi Z, Stenmark-Askmalm M, Liedgren S, Borg A, Loman N, Olsson H, Soller M, Jernström H, Harbst K, Henriksson K, Lindblom A, Arver B, von Wachenfeldt A, Liljegren A, Barbany-Bustinza G, Rantala J, Melin B, Grönberg H, Stattin EL, Emanuelsson M, Ehrencrona H, Rosenquist R, Dahl N.

Author information

  • 1Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. aniaj@sci.pam.szczecin.pl

Abstract

BACKGROUND:

The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity.

METHODS:

To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively.

RESULTS:

There was no evidence of association between the PHB 1630 C>T and MTHFR 677 C>T polymorphisms with either disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had the rare homozygote genotype (TT) of the PHB 1630 C>T polymorphism were at increased risk of both breast and ovarian cancer (HR 1.50, 95%CI 1.10-2.04 and HR 2.16, 95%CI 1.24-3.76, respectively). However, there was no evidence of association under a multiplicative model for the effect of each minor allele.

CONCLUSION:

The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association need to be evaluated in larger series of BRCA1 mutation carriers.

PMID:
22669161
[PubMed - indexed for MEDLINE]
PMCID:
PMC3388557
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk